Infectious Disease Alert – June 1, 2019
June 1, 2019
View Issues
-
Is Fecal Microbiota Transplantation Superior to Fidaxomicin for Recurrent Clostridioides difficile Infection?
In a randomized clinical trial, researchers found the combination of oral vancomycin followed by fecal microbiota transplantation was superior to treatment with fidaxomicin or vancomycin alone for patients with recurrent Clostridioides difficile infection.
-
Vancomycin for MRSA Pneumonia Following Influenza in Children
Coinfection with methicillin-resistant Staphylococcus aureus (MRSA) in children with influenza is associated with high fatality. Data support the addition of a second anti-MRSA antibiotic to vancomycin in severely ill children.
-
Histoplasmosis — Expansion of Risk Areas and Need for More Standardized Practice
Histoplasmosis is increasingly seen beyond the previous risk areas of the Ohio and Mississippi River valleys. Diagnostic and treatment practices vary widely.
-
Omadacycline (Nuzyra)
Omadacycline was approved in 2018 by the U.S. Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
-
Infectious Disease Alert Updates
California Inmates With Cocci Lose Appeal; Tuberculosis Testing in Small Children